Merck ’s MRK stock has declined around 10.3% in the past three months, losing almost $32 billion of its market value.

Merck & Co. said a European Medicines Agency panel recommended expanded approval of the drugmaker's blockbuster cancer treatment Keytruda in two types of gynecologic cancers.

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).

Deep-pocketed investors have adopted a bullish approach towards Merck & Co MRK, and it's something market players shouldn't ...

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...

Merck & Co. has won its first U.S. approval for use of its blockbuster cancer drug Keytruda in patients with malignant pleural mesothelioma, a rare cancer that grows in the membrane that lines the ...

(MRK) said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda in combination with pemetrexed and platinum chemotherapy as a first-line treatment for ...

The FDA previously rejected patritumab deruxtecan over manufacturing issues. Tuesday's study data should boost the companies' case, however.

Lack of a skilled talent pool, and slow logistics operations are among the major challenges that could discourage India’s ...

Health care stocks lagged the S&P 500 in 2023, but they can often be a solid defensive play in an uncertain economy. People don't typically reduce their prescription drug purchases or put ...

Kremlin says Lebanon pager blasts risk igniting tensions in 'explosive' region Merck, a leading science and technology company, launched the first single-use reactor specifically designed to ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.